IP Library Granted Patent US 8,268,791
Granted Patent B2
US 8,268,791 · App. 12/341,696 · Granted Sep 18, 2012

Alkylglycoside compositions for drug administration

Assignee: Aegis Therapeutics, LLC.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,791
App. No.
12/341,696
Granted
Sep 18, 2012
Kind
B2
Abstract

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

Claims (17)

1. A pharmaceutical composition comprising:

a) a triptan analog selected from sumatriptan, naratriptan, zolmitriptan, eletriptan, almotriptan, frovatriptan; and

b) an absorption increasing amount of an alkylglycoside, wherein the alkylglycoside comprises a maltose linked by glycosidic linkage to an alkyl chain comprising between 12 to 16 carbons, and wherein the concentration of alkylglycoside is between 0.05% and 20% by weight.

2. The pharmaceutical composition of claim 1 , wherein the triptan analog is sumatriptan.

3. The pharmaceutical composition of claim 1 , wherein the alkylglycoside is selected from the group consisting of dodecyl maltoside, tridecyl maltoside, and tetradecyl maltoside.

4. The pharmaceutical composition of claim 3 , wherein the alkylglycoside consists of tetradecyl-β-D-maltoside.

5. The pharmaceutical composition of claim 3 , wherein the alkylglycoside consists of dodecyl-β-D-maltoside.

6. The pharmaceutical composition of claim 3 , wherein the alkylglycoside consists of tridecyl-β-D-maltoside.

7. The pharmaceutical composition of claim 1 , wherein the triptan analog is sumatriptan.

8. The pharmaceutical composition of claim 1 , wherein the triptan analog is naratriptan.

9. The pharmaceutical composition of claim 1 , wherein the triptan analog is zolmitriptan.

10. The pharmaceutical composition of claim 1 , wherein the triptan analog is eletriptan.

11. The pharmaceutical composition of claim 1 , wherein the triptan analog is almotriptan.

12. The pharmaceutical composition of claim 1 , wherein the triptan analog is frovatriptan.

13. The pharmaceutical composition of claim 1 , wherein the alkylglycoside is dodecyl maltoside, and wherein the triptan analog is sumatriptan.

14. The pharmaceutical composition of claim 1 , further comprising ethylenediaminetetraacetic acid (EDTA).

15. The pharmaceutical composition of claim 1 , wherein the alkylglycoside is a β-anomer.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2024
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
Reel/Frame 069359/0921 →
SECURITY INTEREST Recorded Aug 6, 2021
From: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057111/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2009
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC.
Reel/Frame 022128/0379 →
Continuity (10)
Continuation In Part 12195192 · Aug 20, 2008
Continuation In Part 12036963 · Feb 25, 2008
Continuation In Part 11193825 · Jul 29, 2005
Continuation In Part 11127786 · May 11, 2005
Provisional Application 60649958 · Feb 3, 2005
Provisional Application 60637284 · Dec 17, 2004
Provisional Application 60632038 · Nov 30, 2004
Provisional Application 60609890 · Sep 14, 2004
Provisional Application 60604296 · Aug 25, 2004
Related Publication 20090163447A1 · Jun 25, 2009